3Singhal S, Mehta J, Desikan R, et al. Antitumoraetivity of thalidomide in refractory multiple myeloma. N Engl J Med, 1999,18:341 : 1565-1571.
4Durie BL, Harousseau JH, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia,2006,20 : 1467- 1473.
5Chng W J, Lau LG,Yusof N, et al. Targeted therapy in multiple myeloma. Cancer Control ,2005,12:91-104.
6Cheng D, Kini AR, Rodriguez J,et al. Microvascular density and cytotoxic T cell activation correlate with response to thalidomide therapy in myeloma patients. Blood, 1999,94 Suppl 1:315a.
7Rosinol L, Cibeira MT, Segarra M, et al. Response to thalidomide in multiple myeloma: impact of angiogenic factors. Cytokine, 2004, 26 : 145-148.
8Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood ,2001 ;98:492-494.
9Li YH,Hou J,Wang DX,et al. Prognostic factors for the efficacy of thalidomide in the treatment of multiple myeloma: a clinical study of 110 patients in China. Leuk Lymphoma ,2006,47:2593-2600.
10Singhal S,Mehta J,Desikan R,et al. Antitumor activity of thalidomide in refractory multiple myeloma[J ]. N Eng J Med, 1999,341 : 1565.
